Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1152/ajpcell.00478.2020 http://scihub22266oqcxt.onion/10.1152/ajpcell.00478.2020 33502950!7938633!33502950     free     free     free       Am+J+Physiol+Cell+Physiol 2021 ; 320 (3): C279-C281 Nephropedia Template TP {{tp|p=33502950|t=2021. Soluble ACE2 as a potential therapy for COVID-19 |pdf=|usr=}}{{33502950}} gab.com Text Soluble ACE2 as a potential therapy for COVID-19 JO: Am J Physiol Cell Physiol http://www.kidney.de/pget.php?&tw=1&pmid=33502950 #FOAvip Soluble angiotensin-converting enzyme 2 (sACE2) could be a therapeutic option to treat coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes ACE2 receptors on cell surfaces to gain intracellular entry, making them an ideal target for therapy. High-affinity variants of sACE2, engineered using high-throughput mutagenesis, are capable of neutralizing COVID-19 infection as decoy receptors. These variants compete with native ACE2 present on cells by binding with spike (S) protein of SARS-CoV-2, making native ACE2 on cell surfaces available to convert angiotensin II to angiotensin-1,7, thus alleviating the exaggerated inflammatory response associated with COVID-19 infection. This article explores the use of sACE2 as potential therapy for COVID-19 infection. Twit Text FOAVip Soluble ACE2 as a potential therapy for COVID-19 ????Am J Physiol Cell Physiol http://www.kidney.de/pget.php?&tw=1&pmid=33502950 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33502950 #FOAvip English Wikipedia <ref>{{Cite pmid|33502950}}</ref> Soluble ACE2 as a potential therapy for COVID-19 #MMPMID33502950 Krishnamurthy S; Lockey RF; Kolliputi N Am J Physiol Cell Physiol 2021[Mar]; 320 (3): C279-C281 PMID33502950show ga Soluble angiotensin-converting enzyme 2 (sACE2) could be a therapeutic option to treat coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes ACE2 receptors on cell surfaces to gain intracellular entry, making them an ideal target for therapy. High-affinity variants of sACE2, engineered using high-throughput mutagenesis, are capable of neutralizing COVID-19 infection as decoy receptors. These variants compete with native ACE2 present on cells by binding with spike (S) protein of SARS-CoV-2, making native ACE2 on cell surfaces available to convert angiotensin II to angiotensin-1,7, thus alleviating the exaggerated inflammatory response associated with COVID-19 infection. This article explores the use of sACE2 as potential therapy for COVID-19 infection. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Angiotensin-Converting Enzyme 2/*therapeutic use[MESH] |Humans[MESH] |Protein Binding[MESH] |Spike Glycoprotein, Coronavirus/metabolism[MESH]Soluble ACE2 as a potential therapy for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing